Novo Nordisk A/S (NONOF)
Makes insulin, weight-loss drugs, and treatments for diabetes and rare blood disorders.
$49.25-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+1.8%
The outlook
NONOF is trading above both its 50- and 200-day moving averages, positioning it in the middle of its 52-week range. Analyst sentiment leans bullish overall. The stock carries a trailing P/E of 11.8, suggesting a relatively modest valuation compared to recent historical levels.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range50% of the way from its 52-week low to high
Market cap
$217.78B
52-wk high
$64.75
52-wk low
$34.00
50-day avg
$46.29
200-day avg
$46.98
Trailing P/E
11.8